CXCR5 and COVID-19: An increased frequency of DN3 B cells with low expression of CXCR5 was reported in severe COVID-19 identified in CD11c- and CD21− DN B cells [15,46], in autoimmune-fibrosis [18], in chronic cutaneous lupus [50], and increased early after Rituximab treatment in SLE [17].